Skip to main content

Advertisement

Table 2 Discontinuance criteria

From: Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study

Severe hypoglycemia
Seriously poor glycemic control such as ≥HbA1c 12.0 % confirmed by second measurement on different day
Offer for participation declined by participants
Deviancy of eligibility after registration
Considered inappropriate to continue the study by investigators due to aggravation of primary disease or complications
Considered inappropriate to continue the study by investigators due to adverse side effects of the study drug
Pregnant
Poor drug adherence (<75 %, or >120 %)
Considered inappropriate to continue the study by investigators due to some other reason